The evidence a regulator reviews, and why phase 2 is not it

Published 24 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
A regulator reviews a submission containing the full clinical programme — usually including phase 3 trials powered for the intended indication — together with manufacturing, quality and non-clinical data, and decides whether the evidence supports approval for a specific indication with specific labelling. Phase 2 results are the basis for designing phase 3, not a substitute for it.

The clinical component

Regulators generally expect adequate and well-controlled trials demonstrating efficacy and characterising safety in the intended population at the intended doses over a relevant duration. For a chronic-use compound in a large population, that means phase 3 trials of thousands of participants over a year or more, with endpoints agreed in advance.

Phase 2 trials of a few hundred participants establish dose-response and inform that design. They do not meet the standard on their own, however large the effect.

The non-clinical and quality components

Toxicology, pharmacology and pharmacokinetic studies in animals; and a complete description of how the product is manufactured, controlled and shown to be consistent batch to batch. The quality component is extensive for a peptide with a fatty-acid modification, because the modification is part of the specification.

None of this is public in the way trials are, and none of it applies to research material, which is made and characterised on a different basis.

What approval would and would not change

Approval would make retatrutide a registered medicine in that jurisdiction, with labelling, pharmacy supply and prescribing. It would not change the chemistry of the molecule or the published trial findings, and research material would remain research material.

Retatrutide is supplied by REVIVE LAB UAE as an investigational research material for laboratory use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not approved for any use anywhere, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Retatrutide Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The clinical component?

Regulators generally expect adequate and well-controlled trials demonstrating efficacy and characterising safety in the intended population at the intended doses over a relevant duration. For a chronic-use compound in a large population, that means phase 3 trials of thousands of participants over a year or more, with endpoints agreed in advance.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Retatrutide Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.